Methyl 3-bicyclo(2.2.1)hept-5-en-2-yl-3-methyloxirane-2-carboxylate
| Common Name: |
Methyl 3-bicyclo(2.2.1)hept-5-en-2-yl-3-methyloxirane-2-carboxylate |
| IUPAC Name: |
methyl 3-(2-bicyclo[2.2.1]hept-5-enyl)-3-methyloxirane-2-carboxylate |
| Molecular Formula: |
C12H16O3 |
| SMILES: |
CC1(C(O1)C(=O)OC)C2CC3CC2C=C3 |
| Inchi: |
1S/C12H16O3/c1-12(10(15-12)11(13)14-2)9-6-7-3-4-8(9)5-7/h3-4,7-10H,5-6H2,1-2H3 |
| Inchi Key: |
PDYPVRXNANFCNW-UHFFFAOYSA-N |
| Cas No: |
72175-33-8 |
| Name |
Value |
| Lipinski Violations |
0 |
| Ghose Violations |
0 |
| Veber Violations |
0 |
| Egan Violations |
0 |
| Muegge Violations |
0 |
| Name |
Value |
| Molecular Weight (g/mol) |
208.25 |
| Mass (g/mol) |
208.11 |
| Molar Refractivity |
55.39 |
| Net Charge |
|
| HBD |
|
| HBA |
3 |
| Rt Bonds |
3 |
| Rings |
3 |
| TPSA |
38.83 |
| Hetero Atoms |
3 |
| Heavy Atoms |
15 |
| Aromatic Heavy Atoms |
0 |
| Melting Point (°C) |
|
| Boiling Point (°C@760.00mm Hg) |
261.00 to 262.00 |
| Vapor Pressure (mmHg@25.00 °C) |
0.012 |
| Vapor Density (Air =1) |
|
| Fraction Csp3 |
0.75 |
| LogP |
1.529 |
| iLOGP |
2.74 |
| XLOGP3 |
1.73 |
| WLOGP |
1.53 |
| MLOGP |
1.77 |
| ESOL Log S |
-2.02 |
| ESOL Solubility (mg/ml) |
1.97 |
| ESOL Solubility (mol/l) |
0.009 |
| ESOL Class: esol_class |
Soluble |
| Ali Log S |
-2.16 |
| Ali Solubility (mg/ml) |
1.43 |
| Ali Solubility (mol/l) |
0.01 |
| Ali Class |
Soluble |
| Silicos-IT LogSw |
-1.18 |
| Silicos-IT Solubility (mg/ml) |
13.8 |
| Silicos-IT Solubility (mol/l) |
0.07 |
| Silicos-IT Class |
Soluble |
| Name |
Value |
| GI Absorption |
High |
| BBB Permeable |
1 |
| PgP Substrate |
0 |
| Log Kp (cm/s) |
-6.34 |
| Bioavailability Score |
0.55 |
| Caco2 |
0 |
| Human Intestinal Absorption |
1 |
| Plasm Protein Binding |
0.771 |
| CYP1A2 Inhibitor |
0 |
| CYP2C19 Inhibitor |
0 |
| CYP2C9 Inhibitor |
0 |
| CYP2D6 inhibitor |
0 |
| CYP3A4 inhibitor |
0 |
| Ames mutagenesis |
0 |
| Acute Oral Toxicity |
1.439 |
| Carcinogenicity (Binary) |
0 |
| Carcinogenicity (Trinary) |
Non-required |
| Eye Irritation |
0 |
| Hepatotoxicity |
0 |
| Androgen Receptor Binding |
1 |
| Aromatase Binding |
0 |
| Estrogen Receptor Binding |
0 |
| Glucocorticoid Receptor Binding |
0 |
| Thyroid Receptor Binding |
0 |
| BRCP inhibitor |
0 |
| BSEP inhibitor |
0 |
| OATP1B1 inhibitor |
1 |
| OATP1B3 inhibitor |
1 |
| OATP2B1 inhibitor |
0 |
| OCT1 inhibitor |
0 |
| OCT2 inhibitor |
0 |
